![Angelo S. Botter](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Loopbaan van Angelo S. Botter
Eerdere bekende functies van Angelo S. Botter
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
MEDEXUS PHARMACEUTICALS INC. | Directeur/Bestuurslid | 10-12-2013 | 02-06-2014 |
Advanced Viral Research Corp.
![]() Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | Directeur/Bestuurslid | 31-05-2006 | 23-03-2009 |
Opleiding van Angelo S. Botter
McGill University | Undergraduate Degree |
Statistieken
Internationaal
Canada | 3 |
Verenigde Staten | 2 |
Operationeel
Director/Board Member | 2 |
Undergraduate Degree | 1 |
Sectoraal
Health Technology | 3 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
MEDEXUS PHARMACEUTICALS INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Advanced Viral Research Corp.
![]() Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | Health Technology |
- Beurs
- Insiders
- Angelo S. Botter
- Ervaring